Halixol

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Halixol

Quick Facts

Property Description
Active Ingredient Ambroxol (as hydrochloride)
Form Tablets, Syrup, Oral Solution
Pharmacological Class Secretolytic and Mucolytic Agent
General Purpose To improve mucus clearance and relieve congestion
Origin Synthetic derivative of Bromhexine

What is Halixol and What Pharmacological Class Does it Belong To?

Halixol is a pharmaceutical preparation whose active component is the substance Ambroxol. This drug is scientifically classified as a mucoactive agent belonging to the secretolytic and mucolytic agent group, a class of medicines recognized for their ability to modify bronchial secretions.

The therapeutic properties are provided by Ambroxol hydrochloride, which is a synthetic compound derived from Bromhexine. The substance liquefies sputum by affecting the mucosal glands in the respiratory tract. This means the medicine helps to thin the thickened secretions that cause chest congestion. As a mono-preparation, Halixol concentrates its physiological action exclusively on these specialized mucoactive effects, positioning it as a targeted intervention for patients experiencing congestion.

How is Halixol Classified by Form and General Purpose?

Halixol is produced for systemic use and is available in multiple common dosage forms, including tablets, a palatable syrup, and oral solution. This multi-form availability is a key differentiating factor, enabling oral use for both adults and the pediatric population where swallowing tablets may be difficult.

The general purpose of this medicine is defined by its core classification: to improve mucus clearance and restore physiological transport functions in the bronchial tubes. By making thick, viscous secretions thinner and less adherent, Halixol ultimately helps to relieve congestion and facilitates the body's effective removal of accumulated secretions. Ambroxol's secretolytic action supports the production of pulmonary surfactant, enhancing the lung's protective mechanisms. This indicates the medicine thins mucus and also supports the lungs' natural defenses.

What side effects are possible with Halixol?

Possible Side Effects and Safety Information

The safety profile for Halixol, which contains the active substance Ambroxol, is defined by specific classifications of adverse reactions across several physiological systems, as documented in official regulatory labeling. These reactions are grouped by frequency and System-Organ Class (SOC).


Frequency-Classified Adverse Reactions

Adverse events most frequently reported are generally related to the Gastrointestinal disorders and Nervous system disorders.

Classification Examples of Officially Listed Adverse Reactions
Common (≥ 1/100 to < 1/10) Nausea, Diarrhoea, Dysgeusia (changed taste), Pharyngeal hypoesthesia (numbness in throat)
Uncommon (≥ 1/1000 to < 1/100) Vomiting, Abdominal pain, Dyspepsia, Dry mouth, Fever
Rare Hypersensitivity reactions, Rash, Urticaria
Not Known Anaphylactic shock, Angioedema, Severe cutaneous adverse reactions (SCARs)

Serious Adverse Reactions and Safety Cautions

The label explicitly documents rare but serious adverse reactions that are classified under Immune system disorders and Skin and subcutaneous tissue disorders. These include Anaphylactic reactions (e.g., Anaphylactic shock and Angioedema) and Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson syndrome (SJS) and Toxic epidermal necrolysis (TEN).

Official regulatory documents require caution in specific patient situations. This includes individuals with severe renal or hepatic impairment due to the potential accumulation of metabolites. Use is not recommended during the first trimester of pregnancy or while breastfeeding. Furthermore, a key safety constraint is the potential for secretions accumulation if the medicine is used concomitantly with cough suppressants, which is generally discouraged.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documentation states that no specific signs of intoxication or severe symptoms have been recorded in humans following an overdose of Ambroxol. Any manifestations experienced are typically extensions of known undesirable effects. These documented symptoms may include short-term restlessness and diarrhoea, along with general gastrointestinal discomfort, such as nausea and vomiting.

Based on pre-clinical data, extreme overdosage is associated with the potential for systemic effects, including hypotension (a drop in blood pressure) and increased salivation (sialorrhea).


Immediate Medical Attention Required

The regulator mandates that any patient who has taken more than the recommended dosage must consult a doctor or seek emergency medical treatment. Immediate medical advice must be sought if signs of a progressive skin rash or mucosal lesions are observed, as this may indicate a serious adverse reaction.


Management and Antidote Information

Management for an overdose is defined as being mainly symptomatic because no specific antidote is known for Ambroxol. Acute measures such as induced vomiting or gastric lavage are generally not indicated and are reserved only for cases of extreme overdosage. Treatment focuses on supporting the patient and managing the reported symptoms.

Therapeutic Uses of Halixol

Halixol (Ambroxol) is used to provide symptomatic support in clinical situations marked by symptoms related to physical discomfort from respiratory congestion and localized throat issues. It plays a role in managing symptoms that create noticeable physiological strain and contributes to improved comfort during acute or chronic episodes.

The medicine is used in situations involving certain distressing symptoms, such as thick mucus and congestion, across both acute and chronic respiratory contexts.


Easing Viscid Mucus and Congestion

Halixol is commonly applied across conditions presenting with acute episodes and chronic conditions characterized by the production of thick, tenacious phlegm. It is used for managing symptoms that create noticeable physiological strain, such as a difficult and unproductive cough. This is relevant for managing symptoms that interfere with daily comfort, which is often needed in conditions such as acute and chronic bronchopulmonary diseases, bronchitis, and bronchiectasis. This generally contributes to easing the overall symptom load and may assist with maintaining functional stability by easing the impact of congestion.


Providing Localized Relief for Acute Sore Throat

The medication is also relevant in clinical settings marked by acute throat discomfort and inflammation, such as pharyngitis. It is applied in addressing the pronounced symptoms of localized pain, especially when swallowing. This provides symptomatic assistance and supports general well-being during symptomatic phases where discomfort may interfere with daily functioning.

Quick Fact: Relief for Congestion
Primary Indication Axis Symptomatic relief for respiratory congestion
Symptom Goal Addressing symptoms related to viscid mucus accumulation
Acute Context Cough and congestion from acute infections
Chronic Context Symptomatic support for chronic bronchitis
Localized Benefit Easing of acute sore throat pain

Eligibility and Restrictions for Use

Who Can and Cannot Use Halixol?

The official eligibility for Halixol (Ambroxol) is strictly defined by regulatory documents based on patient population, medical history, and physiological status.

Contraindicated Populations

Use of this medicine is strictly contraindicated for individuals with a known hypersensitivity to the active substance, Ambroxol, or its related metabolite, Bromhexine. It must also not be used by patients with active gastrointestinal ulcers. Specific formulations may also be contraindicated for individuals with rare hereditary sugar intolerances, such as lactose or fructose intolerance.

Age and Reproductive Status

Halixol is generally approved for use in adults and adolescents over 12 years of age. Eligibility for the pediatric population varies by formulation, with use for children generally starting from 2 years old, although some regional labels explicitly contraindicate use in children up to 2 years of age. Use is not recommended for women in the first trimester of pregnancy and is generally not recommended for breastfeeding mothers.

Conditional Use and Restrictions

Patients with severe renal or hepatic impairment are subject to restrictions and must use the medicine with caution due to the potential for reduced drug clearance. Caution is also necessary for those with a history of peptic ulcer disease or compromised airway motility.

What should I know about interactions with other medicines?

Halixol, which contains the active substance ambroxol, has specific documented interactions with certain categories of other medicinal products, as detailed in official regulatory product information.

Interactions with Cough Suppressants (Antitussives)

Halixol is not recommended for concurrent use with cough suppressants, such as codeine and other antitussive medicines. The reason for this restriction is mechanical: ambroxol works to thin and dissolve thick respiratory secretions (sputum). When combined with a cough suppressant that depresses the cough reflex, the resulting accumulation of the dissolved sputum may occur, posing a risk of airway obstruction.

Interactions with Antibiotics

The simultaneous use of Halixol with certain antibiotics (specifically amoxicillin, cefuroxime, erythromycin, and doxycycline) is documented to have an effect. Ambroxol acts to increase the concentration of these antibiotics within the lung parenchyma (lung tissue). This effect can potentially be beneficial by enhancing the penetration of the antibiotic into the site of infection in the respiratory tract. No other clinically significant unfavorable interactions with other medicinal products have been observed or reported in official documentation.

Mechanism of Action

How Halixol Works

Halixol, containing Ambroxol, executes its function within the respiratory tract by employing a multi-faceted pharmacodynamic mechanism focused on modulating the viscosity and transport of bronchial secretions. The core mechanism involves secretolysis through the stimulation of serous cells in the submucosal glands, increasing the volume of low-viscosity, watery fluid. Simultaneously, the drug exerts a direct mucolytic effect by chemically degrading and depolymerizing the acid mucopolysaccharide fibers in the phlegm, which reduces the viscosity and inherent adhesion of bronchial secretions.

Furthermore, the drug promotes the synthesis and release of pulmonary surfactant from Type II pneumocytes. Surfactant acts as a crucial anti-adhesion factor, reducing surface tension within the airways. This less-adhesive, thinned mucus, combined with the drug's modulation of the ciliary beat frequency, affects the natural mucociliary clearance (MCC) pathway, supporting ciliary-mediated transport of secretions.

Secondary actions include mild anti-inflammatory effects through the modulation of cytokine release and antioxidant activity. A distinct mechanism involves the blockade of neuronal voltage-gated Na^+ channels, which alters local afferent nerve signaling along the mucosal lining.

Dosage and Administration Information

How Halixol is Used: Administration Guidelines

Halixol, which contains the active substance Ambroxol, is utilized following established protocols for administration. The medication is intended for oral use through its various conventional forms, including tablets, syrup, and solution.

Dosing and Schedule Patterns

Administration typically follows a two-phase regimen for adults and adolescents aged 12 years and older. The initial phase involves a higher frequency of 30 mg taken three times daily (t.i.d.) and is followed by a maintenance phase of 30 mg taken twice daily (b.i.d.). Sustained-release forms (75 mg) are intended for administration once daily.

Administration Constraint Labeled Instruction
Timing Relative to Meals Must be taken after meals
Hydration Requirement Ingestion must be accompanied by a sufficient amount of liquid
Acute Use Duration Treatment for acute conditions should generally not exceed 4 to 7 days without further medical review

Population-Specific Use

Standard guidelines indicate that dosage must be reduced or the interval between administrations extended for individuals diagnosed with severe renal or hepatic impairment. Specific, lower dosage regimens are also established for the pediatric population utilizing the syrup or oral solution forms.

Recent Clinical Evidence

Research evidence / Overview of studies for Halixol

Evidence for Use in Chronic Bronchopulmonary Diseases

Research was studied for symptomatic support in chronic respiratory conditions, such as chronic bronchitis, where outcomes related to physical discomfort due to thickened mucus are common. Studies monitored patient-reported experiences and functional outcomes related to conditions characterized by fluctuating or episodic manifestations. The available evidence includes randomized controlled trials (RCTs) and systematic reviews. Studies observed responses over defined time intervals, focusing on how chronic symptoms evolved. While some findings describe patterns related to the monitored frequency of acute episodes, other specific trials have reported patterns of less difference when compared directly to a placebo for overall measured outcomes. This suggests that certainty remains low for comprehensive, long-term outcomes across all metrics.


Evidence for Use in Acute Respiratory Conditions

Research has examined the role of Halixol in acute respiratory tract diseases, such as acute bronchitis. The main evidence comes from short-term placebo-controlled RCTs that focused on outcomes related to systemic or functional imbalance during periods of heightened symptom activity. Findings from these short-term studies report how symptoms evolved in the observed populations, and studies monitored changes in both cough severity and expectoration difficulty scores. RCTs have documented measured changes in sputum characteristics. However, the overall evidence is limited by the fact that many acute respiratory infections are self-limiting, making it challenging to separate patterns related to the product from the body’s natural recovery.


Evidence for Localized Relief of Acute Sore Throat

Halixol, particularly in lozenge form, was studied for localized pain in adults experiencing acute, uncomplicated sore throat. The evidence base primarily consists of systematic reviews and meta-analyses of several randomized trials. The main focus of this research was on patient-reported outcomes describing perceived discomfort, specifically pain intensity scores measured over very short, defined time intervals. Findings indicate that patterns related to pain intensity was observed in some studies compared to placebo during this initial short-term window. However, when researchers monitored outcomes over longer periods, findings were mixed, and certainty remains low.

Frequently Asked Questions (FAQ)

Common questions about Halixol (FAQ)


Q: Can Halixol be taken with or without food?

Official administration guidelines indicate that Halixol is typically used after meals. This is the condition described in regulatory documents regarding its administration.


Q: Does Halixol help with a dry cough or a wet cough?

Halixol is classified as a secretolytic and mucolytic agent. Its mechanism is described as supporting mucus transport in conditions associated with abnormal secretions. This action typically relates to assisting with a productive, or 'wet,' cough to facilitate expectoration.


Q: Does taking Halixol make you sleepy?

Official documents list adverse reactions under the classification of Nervous system disorders. Drowsiness has been reported in association with the active substance, but the frequency may vary depending on the specific formulation. This is listed as a documented undesirable effect.


Q: Can people with diabetes use Halixol?

Certain liquid formulations of the active substance are documented to contain ingredients like sorbitol or other sweeteners. Regulatory information indicates that the presence of these substances may require caution for individuals with known intolerances to specific sugars. Information on excipients is found in the official product labeling.


Q: Why is it sometimes recommended to drink plenty of fluids while using Halixol?

The mechanism of action for Halixol is described as secretolytic, which involves the thinning of mucus secretions. Official prescribing information specifies the need for sufficient fluid intake during use, as the mechanism relies on adequate hydration to support the transport and clearance of these thinned secretions from the airways.


Q: Is Halixol known to cause stomach upset?

Gastrointestinal disorders are the most frequently reported category of adverse events documented in official regulatory labeling. Common reports include nausea, and uncommon reports involve vomiting, abdominal pain, and general dyspepsia (indigestion).


Q: Is it normal to feel a change in taste after taking Halixol?

According to official regulatory documents, a changed sense of taste, known as dysgeusia, is listed under the Common frequency classification for adverse reactions.


Q: What is the risk of an allergic reaction to Halixol?

The medicine is strictly contraindicated for individuals with known hypersensitivity to the active substance. Official safety documents mention rare reports of hypersensitivity reactions. More severe reactions, such as anaphylactic shock and severe cutaneous adverse reactions (SCARs), have also been documented in regulatory data.


Q: Why do official documents state that Halixol should not be used with certain other medicines?

The main restriction is due to a mechanical risk when combined with cough suppressants, such as antitussives. Halixol thins and dissolves mucus, and if the cough reflex is suppressed, the thinned mucus may accumulate, posing a risk of airway obstruction.


Q: Why is Halixol not recommended for people with certain stomach conditions?

The restriction for those with active gastrointestinal ulcers or a history of peptic ulcer disease is based on the potential for mucolytic products to weaken the protective gastric mucosal barrier.


Q: Are there different strengths of Halixol available?

The active substance in Halixol is available in various forms and strengths. These generally include 30 mg tablets, 75 mg sustained-release forms, and liquid forms, such as syrups or oral solutions, which have specific concentrations for different populations.


Q: What should I do if I notice a rash while using Halixol?

Due to the documented association with severe cutaneous adverse reactions (SCARs), official warnings specify that discontinuation of treatment may be considered as a precaution if new skin or mucosal lesions occur.


Q: How quickly am I supposed to feel the effects of Halixol?

The time it takes for the medicine to become available in the body is indicated by its pharmacokinetics. For oral use, the active substance typically reaches its peak concentration in the blood plasma approximately two hours after intake of a single dose.


Q: What happens if I miss a scheduled time to use Halixol?

Regulatory information generally includes guidance that if a dose is missed, it is often recommended to take it as soon as remembered. However, if it is almost time for the next scheduled dose, the missed dose is typically skipped to avoid taking two doses at once.


Q: Does Halixol contain alcohol?

Certain liquid formulations, such as syrups, are documented to contain ethanol (alcohol). Official warnings state that the presence of ethanol may pose a risk for individuals who are alcoholic or for those with liver disease or epilepsy.


Q: Does taking Halixol cause dizziness?

Dizziness is listed as an undesirable effect in some official documents relating to the active substance. Because this is a documented central nervous system effect, it may potentially affect the ability to drive or operate machinery.


Q: Is there evidence that Halixol can be used by people with asthma?

Clinical use is generally for bronchopulmonary diseases associated with abnormal mucus secretion and impaired mucus transport. For specific underlying conditions, such as asthma, the decision for use typically relies upon individual patient assessment.


Q: Does Halixol contain any sugars or artificial sweeteners?

Certain liquid formulations are documented to contain both artificial sweeteners, like saccharin, and other ingredients like sorbitol. The presence of these components is often detailed in the excipients section of the product labeling.


Q: What are the official guidelines for stopping Halixol use?

Regulatory documents generally include guidance that discontinuation of the medicine is typically done upon the instruction of a healthcare professional. For use in acute conditions, official prescribing information often limits continuous use to a few days without further medical review.


Q: How long does the effect of Halixol last?

The duration of the active substance in the body is measured by its biological half-life. This is reported to be approximately 8 to 10 hours after repeated dosing, which represents the period during which half of the drug remains in the system.


Q: Where can I find the official regulatory documents for Halixol?

Official information is made available in documents such as the Summary of Product Characteristics (SmPC) and patient information leaflets. These can typically be found on the websites of national regulatory authorities like the EMA, MHRA, or national drug agencies.


Q: Is Halixol a prescription-only medicine?

In certain regions and for specific forms, Halixol is classified as an Over-The-Counter (OTC) medicine. This classification means it may be available for use without needing a prescription.

How should Halixol be stored and disposed of?

The official product labeling for Halixol (Ambroxol) defines specific conditions for storage and disposal to maintain the medicine's quality.

Storage Requirements

Labeled Storage Temperature Requirements Store below 30 C
Light/Moisture Protection Requirements Protect from light
Stability After Opening (Syrup/Solution) Must be used within 28 days

Handling and Disposal

  • The medicine must be kept out of the sight and reach of children at all times.
  • The oral solution/syrup should be stored in the original container to maintain stability.
  • Disposal of all unused or expired Halixol and related waste must be carried out in accordance with local regulations and established pharmaceutical waste management protocols.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Halixol found in:

A-Z Index: